Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
SIMPLE SUMMARY: ALK-rearranged non-small cell lung cancer treatment has radically changed in the last few years thanks to the development of ALK inhibitors, which clearly improved survival. To our knowledge, even though many studies correlate body mass index (BMI) with lung cancer immunotherapy, con...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340506/ https://www.ncbi.nlm.nih.gov/pubmed/37444532 http://dx.doi.org/10.3390/cancers15133422 |